Cytosorbents Corp Files 8-K on Financials
Ticker: CTSO · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1175151
| Field | Detail |
|---|---|
| Company | Cytosorbents CORP (CTSO) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K, corporate-actions
Related Tickers: CTSO
TL;DR
CYTOSORBENTS CORP (CTSO) filed an 8-K on Jan 13, 2025, detailing financial results and operations.
AI Summary
Cytosorbents Corporation filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company was formerly known as MedaSorb Technologies CORP and Gilder Enterprises Inc.
Why It Matters
This 8-K filing provides crucial updates on Cytosorbents Corporation's financial performance and operational status, which is important for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial results and does not appear to contain any immediately alarming or significant negative news.
Key Players & Entities
- Cytosorbents Corporation (company) — Registrant
- MedaSorb Technologies CORP (company) — Former Company Name
- GILDER ENTERPRISES INC (company) — Former Company Name
- January 13, 2025 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Cytosorbents Corporation's results of operations and financial condition, along with Regulation FD disclosures and financial statements and exhibits.
When was this 8-K filing submitted?
This 8-K filing was submitted on January 13, 2025.
What were Cytosorbents Corporation's previous names?
Cytosorbents Corporation was formerly known as MedaSorb Technologies CORP and GILDER ENTERPRISES INC.
Where is Cytosorbents Corporation's principal executive office located?
Cytosorbents Corporation's principal executive office is located at 305 College Road East, Princeton, New Jersey 08540.
What is the Commission File Number for Cytosorbents Corporation?
The Commission File Number for Cytosorbents Corporation is 001-36792.
Filing Stats: 560 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-01-13 09:05:31
Key Financial Figures
- $0.001 — e on which registered Common Stock, $0.001 par value CTSO The Nasdaq Stock Marke
Filing Documents
- tm253092d1_8k.htm (8-K) — 27KB
- tm253092d1_ex99-1.htm (EX-99.1) — 24KB
- tm253092d1_ex99-1img001.jpg (GRAPHIC) — 43KB
- 0001104659-25-002898.txt ( ) — 287KB
- ctso-20250113.xsd (EX-101.SCH) — 3KB
- ctso-20250113_lab.xml (EX-101.LAB) — 33KB
- ctso-20250113_pre.xml (EX-101.PRE) — 22KB
- tm253092d1_8k_htm.xml (XML) — 3KB
02
Item 2.02 Results of Operation and Financial Condition On January 13, 2025, CytoSorbents Corporation issued a press release announcing the conclusion of its subscription period and preliminary results of its Rights Offering, which commenced on December 9, 2024, including certain preliminary and unaudited financial results and business updates for the quarter and year ended December 31, 2024. A copy of the press release is furnished herewith as Exhibit 99.1.*
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure The information set forth above in Item 2.02 of this Current Report on Form 8-K is incorporated herein by reference.*
01
Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of the Company, dated January 13, 2025 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) * The information in Items 2.02 and 7.01 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 13, 2025 CYTOSORBENTS CORPORATION By: /s/ Dr. Phillip P. Chan Name: Dr. Phillip P. Chan Title: Chief Executive Officer